Sun Pharma says US court denies motion on Protonix

BANGALORE, July 19 (BestGrowthStock) – Sun Pharmaceutical (SUN.BO: )
said a U.S. court had denied its motion to reverse a jury
verdict of infringement against the Indian firm on Pfizer’s
(PFE.N: ) Protonix acid reflux drug patent that the jury had said
was valid.

In a statement dated July 17, Sun said it was not
prohibited from selling the drug before the expiry of Pfizer’s
marketing exclusivity in January 2011, as its other claims
concerning the validity of the patents, including patent
misuse, were still pending.

In April, a jury in the U.S. District Court for New Jersey
had rejected allegations by Teva and Sun Pharmaceutical that
the patent on the widely used drug was obvious and should be
declared invalid. [ID:nN23219271]

The original patent on Protonix, known chemically as
pantoprazole, is held by Swiss drugmaker Nycomed [NYCMD.UL] and
was licensed to Wyeth, which is now owned by Pfizer.

Nycomed and Wyeth filed their patent infringement lawsuit
against Teva and Sun in May 2004.
(Reporting by Bharghavi Nagaraju; Editing by Ranjit

Sun Pharma says US court denies motion on Protonix